Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Oxidative Stress Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NQO1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NQO1 Wild-Type (WT) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Perfect for enzymatic assay setup. |
View NQO1 Products |
| Mutant Antigen | NQO1 (Pro187Ser) Mutant Protein The common C609T polymorphism variant. Crucial for counter-screening and patient stratification assays. |
View NQO1 Products |
| Gene Delivery | NQO1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for intracellular ROS and cytotoxicity assays. |
View NQO1 Products |
| Benchmark Ab | Anti-NQO1 Recombinant Antibody High-affinity positive control clone for Western Blot, IHC, and ELISA validation. |
View NQO1 Products |
| Validator | NQO1 siRNA Set Target-specific knockdown pool for validating NQO1-dependent pathway activation and drug specificity. |
View NQO1 Products |
| Related Target A | Nrf2 (NFE2L2) Master transcriptional regulator of NQO1. Essential for upstream pathway modulation and synergy studies. |
View Nrf2 Products |
| Related Target B | Keap1 The sensor protein regulating Nrf2 degradation, directly controlling downstream NQO1 expression levels. |
View Keap1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Polymorphism Off-Target Effects (C609T/Pro187Ser) | Both WT NQO1 and Pro187Ser mutant proteins available with >95% purity for differential enzymatic profiling. |
| Intracellular Target Accessibility | High-titer Lentivirus particles designed for robust stable cell line construction to run cell-based functional assays. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies and positive control proteins included in the catalog. |
| Enzymatic Assay False Positives | Target-specific siRNA pools included for loss-of-function validation in tumor cell lines. |
Live NQO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of NQO1 (NAD(P)H quinone dehydrogenase 1) is undergoing a major renaissance. Historically viewed as a cytosolic detoxifying enzyme, NQO1's dramatic over-expression in solid tumors—such as pancreatic, non-small cell lung (NSCLC), breast, and colorectal cancers—has positioned it as a highly selective bioactivator for prodrug design. The race for NQO1 therapeutics is intensifying, with major players shifting focus from traditional non-selective cytotoxic agents to NQO1-targeted small molecule prodrugs and synthetic lethal combinations. As first-generation therapies reach the clinic, the next wave of R&D is targeting the Nrf2/Keap1/NQO1 axis to overcome therapeutic resistance and exploit metabolic vulnerabilities in KRAS-mutant and Nrf2-addicted cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Prodrugs | Enbiotix, Clinical Stage Candidates (e.g., Beta-Lapachone derivatives) | Pancreatic Cancer, NSCLC, Glioblastoma | Enzymatic Kinetic Assays (Need highly stable WT NQO1 Recombinant Protein) |
| Synthetic Lethality / Combination | Academic Medical Centers, Biotech Startups | Solid Tumors with Nrf2/Keap1 mutations | Pathway Validation (Need Keap1/Nrf2 pathway target proteins and siRNA) |
| Targeted Inhibitors | Oncology-focused Biopharma | Chemo-sensitization, Inflammatory diseases | Selectivity Assay (Need NQO1 WT vs. Polymorphic Mutant Proteins) |